Clinical trial: impact of prior infliximab therapy on the clinical response to certolizumab pegol maintenance therapy for Crohn's disease.


BACKGROUND Certolizumab pegol (CZP) is an effective therapy for Crohn's disease refractory to aminosalicylates, corticosteroids and immunosuppressants. In PRECiSE 2, patients were also eligible for enrolment if prior infliximab therapy was terminated due to loss of response. AIM To evaluate prior infliximab therapy on sustained response and remission to… (More)
DOI: 10.1111/j.1365-2036.2010.04360.x


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics